Background: Acute ischemic stroke (AIS) is closely related to the level of inflammatory factors. This study aimed to explore the correlation between interleukin-6 (IL-6), interleukin-8 (IL-8), and the modified early warning score (MEWS) of AIS patients and their condition and prognosis. Methods:The clinical data of 95 AIS patients admitted to our hospital from January 2019 to October 2019 were selected, and 91 cases were finally recruited to the study group according to the inclusion and exclusion criteria. A control group was recruited comprising 70 healthy patients. The differences in IL-6 and IL-8 levels between the 2 groups were compared. Multiple logistic regression analysis was used to analyze the independent risk factors affecting the prognosis of AIS patients. A receiver-operating characteristic (ROC) curve was used to analyze the predictive value of IL-6, IL-8, and MEWS for the poor prognosis of AIS patients.Results: The levels of IL-6 and IL-8 in the study group were higher than those of the control group (P<0.05). After 90 days of treatment, 69 cases in the study group allocated into the good prognosis group, and 22 were allocated into the poor prognosis group. The National Institutes of Health Stroke Scale (NIHSS) scores before thrombolysis, blood glucose before thrombolysis, systolic blood pressure 2 h after thrombolysis, IL-6, IL-8, and MEWS scores within 24 h of admission in the good prognosis group were lower than those of the poor prognosis group (P<0.05). The area under the curve (AUC) of IL-6, IL-8, MEWS, and the 3 combined curves were 0.937, 0.897, 0.839, and 0.976, respectively, and the area under the combined detection curve was the largest. Conclusions:The inflammatory response and secondary brain damage after AIS are influenced by IL-6 and IL-8. Combined with the MEWS score, IL-6 and IL-8 can be used as important indicators to judge the severity of the early condition of AIS patients. The combination of these 3 indicators has high accuracy in evaluating the prognosis of patients and is worthy of clinical promotion.
BackgroundAlthough more and more clinical studies have shown that acupuncture as an auxiliary combined with Western medicine is effective in the treatment of patients with epilepsy, no systematic reviews of acupuncture as a treatment for epilepsy have been published. Hence, we conducted this meta-analysis to evaluate the effect of acupuncture treatment on patients with epilepsy.MethodsThis study retrieved randomized controlled trials (RCTs) of acupuncture treatment for epilepsy from various electronic databases including PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Chinese BioMedical Literature Database, and Wangfang database. These studies evaluated the effectiveness of acupuncture as an auxiliary treatment combined with Western medicine for patients with epilepsy. The methodological quality of the studies was assessed using the Cochrane Handbook for Systematic Reviews of Interventions.ResultsA total of 17 RCTs involving a total of 1,389 participants were included. The results showed that acupuncture combined with Western medicine improved the effective rates of treatment (OR: 4.28; 95% CI: 3.04–6.02; p < 0.001), and reduced the seizure frequency of patients (SMD: −3.29; 95% CI: −3.51 to −3.07; p < 0.001) and the EEG discharge frequency (SMD: −5.58; 95% CI: −7.02 to −4.14; p < 0.001). Regarding the quality of life and adverse events, the acupuncture group was superior to the control group in improving the overall quality of life of patients with epilepsy (SMD: 14.41; 95% CI: 12.51–16.32; p < 0.001) and decreased adverse events (OR: 0.38; 95% CI: 0.23–0.63, p < 0.001).ConclusionThe results of the analysis suggested that acupuncture combined with Western medicine is probably helpful in patients with epilepsy, but strong supportive data are not yet available. Given that this study is based on a low to moderate evidence-based analysis, the conclusions should be viewed with caution.Systematic review registrationPROSPERO, identifier no. CRD42023409923.
Introduction: Growing evidence demonstrated the occurrence of neurological complications such as ischemic stroke, epilepsy, and autoimmune encephalitis ( AE ) associated with COVID − 19 infection. The purpose of this review was to summarize the clinical symptoms, treatment, and outcome of COVID-19-associated AE. Methods: We searched case reports and case series of AE associated with COVID-19 between January 1, 2020, and March 31, 2023, using Pubmed, Embase, and Web of Science databases. After screening and further evaluation, irrelevant articles were excluded. Information related to treatment, clinical manifestations, comorbidities, and outcomes was extracted and summarized. Results: 36 studies were included in this review, 34 of which were case reports and 2 were case series. A total of 39 patients with AE were included, including 18 (46%) cases of unknown type of AE, 10 (26%) cases of anti-N-methyl-D-aspartate (NMDA) encephalitis, 4 (10%) cases of limbic encephalitis, 3 (8%) cases of anti-myelin-oligodendrocyte-glycoprotein (MOG) encephalitis, and other type of AE. In addition, the clinical manifestations of AE are mainly disturbance of consciousness, seizure and psychiatric symptoms. Although the symptoms of AE are varied, most patients could recover completely, with a few having residual symptoms of neurological damage. Conclusions: In this systematic review, the characteristics of COVID-19-associated AE are summarized, including neurological manifestations, treatment, types, and outcomes. Although COVID−19-associated AE can sometimes be life-threatening, most AE is reversible if treated promptly.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.